


Tgw



PATENT
Attorney Docket No. 056291-5241

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **HENNEQUIN et al.**)
Application No.: **10/573,090**)
Filed: **March 15, 2006**)
For: **QUINAZOLINE DERIVATIVES AS**
TYROSINE KINASE INHIBITORS)

)
Group Art Unit: **1751**
)
Examiner: *Unassigned*
)
Date: **April 20, 2007**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)


Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a
CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.
§1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: April 20, 2007
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5241	Application No. 10/573,090	
				Applicants: HENNEQUIN <i>et al.</i>		
				Filing Date: March 15, 2006	Group Art Unit: 1751	
U.S. PATENT DOCUMENTS						
Initial		Document No.	Date	Name	Class	
					Sub-Class	
					Filing Date	
FOREIGN PATENT DOCUMENTS						
		Document No.	Date	Country	Class	
					Sub-Class	
					Translation	
1.		DE 10040527	February 28, 2002	Germany		Claims
2.		WO 00/09481	February 24, 2000	WIPO		Claims
3.		WO 02/062767	August 15, 2002	WIPO		Claims
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)						
	4.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" Bioorg Med Chem Lett. 16(6):1633-1637 (2006)				
	5.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005)				
	6.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006)				
	7.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" Tetrahedron letters 46(43): 7381-7384 (2005)				
	8.	Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" Tetrahedron letters 46(45):7715-7719 (2005)				
	9.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett. 16(10):2672-2676 (2006)				
Examiner		Date Considered				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.